Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).
Fragai, M., Comito, G., Di Cesare Mannelli, L., Gualdani, R., Calderone, V., Louka, A., Richichi, B., Francesconi, O., Angeli, A., Nocentini, A., Gratteri, P., Chiarugi, P., Ghelardini, C., Tadini-Buoninsegni, F., Supuran, C.T., Nativi, C.(2017) J Med Chem 60: 9003-9011
- PubMed: 29048889 
- DOI: https://doi.org/10.1021/acs.jmedchem.7b01237
- Primary Citation of Related Structures:  
5N5J, 5N5K - PubMed Abstract: 
Oxaliplatin (OXA) is a valuable and largely used cancer drug which induces a serious and intractable neuropathy. The lipoyl-homotaurine derivative (ADM_12) reverts in vivo OXA-induced neuropathy, and it is an effective antagonist of the nociceptive sensor channel TRPA1. Unprecedentedly, this safe analgesic showed a synergy with OXA in vitro and proved to inhibit CA IX, a relevant therapeutic target, clearly interfering with pancreatic cancer cells' aggressiveness.
Organizational Affiliation: 
Department of Chemistry, University of Florence , via della Lastruccia 3-13, 50019 Sesto Fiorentino, Italy.